[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100605385":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":33,"centralContacts":38,"locations":48,"responsibleParty":207,"collaborators":209,"id":211,"slug":212,"hasResults":213,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":42,"eligibilityCriteria":217,"healthyVolunteers":213,"sex":218,"minAge":219,"maxAge":42,"enrollmentInfo":220,"targetDuration":42,"studyType":223,"phases":224,"briefSummary":226,"conditions":227,"keywords":229,"overallStatus":51,"whyStopped":42,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":241},{"fullName":5,"class":6},"Omeza, LLC","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"OCM + SOC","EXPERIMENTAL","Omeza® Complete Matrix (OCM™) is a wound care matrix comprised of hydrolyzed fish collagen derived from whitefish skin",[13],"Device: Omeza® Complete Matrix",{"label":15,"type":16,"description":17,"interventionNames":18},"Standard of Care","ACTIVE_COMPARATOR","Surgical sharp debridement, offloading (TCC gold standard, fixed ankle-walker alternative), and proper moisture balance",[19],"Other: Standard of Care",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DEVICE","Omeza® Complete Matrix","OCM Application, Surgical sharp debridement, offloading (TCC gold standard, fixed ankle-walker alternative), and proper moisture balance",[9],[27],"OCM",{"type":29,"name":15,"description":17,"armGroupLabels":30,"otherNames":31},"OTHER",[15],[32],"SOC",[34],{"name":35,"affiliation":36,"role":37},"Angelina Ferguson, DNP","SygNola, LLC","STUDY_DIRECTOR",[39,44],{"name":35,"role":40,"phone":41,"phoneExt":42,"email":43},"CONTACT","9866294013",null,"dr.aferguson@sygnola.com",{"name":45,"role":40,"phone":46,"phoneExt":42,"email":47},"Sarah Moore, MBE","986-629-4013","sarah.moore@sygnola.com",[49,70,86,101,116,131,146,162,177,193],{"facility":50,"status":51,"city":52,"state":53,"zip":54,"country":55,"countryCode":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":63},"SitePath Research","RECRUITING","Evergreen Park","Illinois","60805","United States","US",{"type":58,"coordinates":59},"Point",[60,61],-87.70172,41.72059,{"lat":61,"lon":60},[64,67],{"name":65,"role":40,"phone":42,"phoneExt":42,"email":66},"Ana Petrovic","apetrovic@sitepathresearch.com",{"name":68,"role":69,"phone":42,"phoneExt":42,"email":42},"Bela Pandit, DPM","PRINCIPAL_INVESTIGATOR",{"facility":71,"status":51,"city":72,"state":73,"zip":74,"country":55,"countryCode":56,"cosmosGeoPoint":75,"geoPoint":79,"contacts":80},"MedCentris of Denham Springs","Denham Springs","Louisiana","70726",{"type":58,"coordinates":76},[77,78],-90.95753,30.4874,{"lat":78,"lon":77},[81,84],{"name":82,"role":40,"phone":42,"phoneExt":42,"email":83},"Tabatha Yent, LPN","Tabatha.yent@medcentris.com",{"name":85,"role":69,"phone":42,"phoneExt":42,"email":42},"Monique Consoer, NP",{"facility":87,"status":51,"city":88,"state":73,"zip":89,"country":55,"countryCode":56,"cosmosGeoPoint":90,"geoPoint":94,"contacts":95},"MedCentris of Leesville","Leesville","71446",{"type":58,"coordinates":91},[92,93],-93.261,31.14352,{"lat":93,"lon":92},[96,99],{"name":97,"role":40,"phone":42,"phoneExt":42,"email":98},"Brandi Shuff, LPN","Brandi.shuff@medcentris.com",{"name":100,"role":69,"phone":42,"phoneExt":42,"email":42},"Stefanie Corley, NP",{"facility":102,"status":51,"city":103,"state":73,"zip":104,"country":55,"countryCode":56,"cosmosGeoPoint":105,"geoPoint":109,"contacts":110},"MedCentris of Marksville","Marksville","71351",{"type":58,"coordinates":106},[107,108],-92.06624,31.12797,{"lat":108,"lon":107},[111,114],{"name":112,"role":40,"phone":42,"phoneExt":42,"email":113},"Laura Whittington","laura.whittington@medcentris.com",{"name":115,"role":69,"phone":42,"phoneExt":42,"email":42},"Averie Rachal, NP",{"facility":117,"status":51,"city":118,"state":73,"zip":119,"country":55,"countryCode":56,"cosmosGeoPoint":120,"geoPoint":124,"contacts":125},"MedCentris of Slidell","Slidell","70458",{"type":58,"coordinates":121},[122,123],-89.78117,30.27519,{"lat":123,"lon":122},[126,129],{"name":127,"role":40,"phone":42,"phoneExt":42,"email":128},"Donyille Singletary, RN","donyille.singletary@medcentris.com",{"name":130,"role":69,"phone":42,"phoneExt":42,"email":42},"Natalie Dean, FNP",{"facility":132,"status":51,"city":133,"state":73,"zip":134,"country":55,"countryCode":56,"cosmosGeoPoint":135,"geoPoint":139,"contacts":140},"MedCentris of Vidalia","Vidalia","71373",{"type":58,"coordinates":136},[137,138],-91.42595,31.56544,{"lat":138,"lon":137},[141,144],{"name":142,"role":40,"phone":42,"phoneExt":42,"email":143},"Taylor Estis","taylor.estis@medcentris.com",{"name":145,"role":69,"phone":42,"phoneExt":42,"email":42},"Shanda Jackson, NP",{"facility":147,"status":51,"city":148,"state":149,"zip":150,"country":55,"countryCode":56,"cosmosGeoPoint":151,"geoPoint":155,"contacts":156},"MedCentris of Cleveland","Cleveland","Mississippi","38732",{"type":58,"coordinates":152},[153,154],-90.72482,33.744,{"lat":154,"lon":153},[157,160],{"name":158,"role":40,"phone":42,"phoneExt":42,"email":159},"Paige Livingston","courtney.livingston@medcentris.com",{"name":161,"role":69,"phone":42,"phoneExt":42,"email":42},"Shauna Allen, FNP",{"facility":163,"status":51,"city":164,"state":149,"zip":165,"country":55,"countryCode":56,"cosmosGeoPoint":166,"geoPoint":170,"contacts":171},"MedCentris of Southaven","Southaven","38671",{"type":58,"coordinates":167},[168,169],-90.01259,34.98898,{"lat":169,"lon":168},[172,175],{"name":173,"role":40,"phone":42,"phoneExt":42,"email":174},"Juliase Walls, LPN","juliase.walls@medcentris.com",{"name":176,"role":69,"phone":42,"phoneExt":42,"email":42},"Carlene McAllister, NP",{"facility":178,"status":51,"city":179,"state":180,"zip":181,"country":55,"countryCode":56,"cosmosGeoPoint":182,"geoPoint":186,"contacts":187},"Gentle Foot Care","Newark","Ohio","43055",{"type":58,"coordinates":183},[184,185],-82.40126,40.05812,{"lat":185,"lon":184},[188,191],{"name":189,"role":40,"phone":42,"phoneExt":42,"email":190},"Mandy Wilson","awilson@ohiofootspecialists.com",{"name":192,"role":69,"phone":42,"phoneExt":42,"email":42},"Jeffrey Wilson, DPM",{"facility":178,"status":51,"city":194,"state":180,"zip":195,"country":55,"countryCode":56,"cosmosGeoPoint":196,"geoPoint":200,"contacts":201},"Sylvania","43560",{"type":58,"coordinates":197},[198,199],-83.71299,41.71894,{"lat":199,"lon":198},[202,205],{"name":203,"role":40,"phone":42,"phoneExt":42,"email":204},"Betsy Naugle","bmn1016@gmail.com",{"name":206,"role":69,"phone":42,"phoneExt":42,"email":42},"Gregory Black, DPM",{"type":208,"investigatorFullName":42,"investigatorTitle":42,"investigatorAffiliation":42,"oldNameTitle":42,"oldOrganization":42},"SPONSOR",[210],{"name":36,"class":6},"100605385","evaluating-the-efficacy-of-ocm-omeza-complete-matrix-in-the-treatment-of-diabetic-foot-ulcers-100605385",false,"NCT07161830","Evaluating the Efficacy of OCM™ (Omeza® Complete Matrix) in the Treatment of Diabetic Foot Ulcers","Evaluation of the Efficacy of Omeza® Complete Matrix in the Healing of Chronic Diabetic Foot Ulcers: A Randomized Controlled Multicenter Crossover Trial","Inclusion Criteria:\n\n1. Male or Female, 18 years of age or older\n2. Subject has a medical diagnosis of Type I or Type II Diabetes Mellitus requiring oral or glycemic control and\u002For insulin replacement therapy\n3. Subject has a diabetic foot ulcer present for 4 weeks or greater (documented in medical record), and less than 12 months duration if being treated with continuous SOC\n4. Subject has a diabetic foot ulcer with a historical wound measurement showing less than 25% healing in 14 days prior to screening\n5. Subject has a diabetic foot ulcer with screening wound measurement showing less than 25% healing in 14 days prior to randomization\n6. Subject has a diabetic foot ulcer of Wagner grade 1, 2, or 3 without infection or clinically visible exposed bone. Wagner 3 is acceptable if the diagnosis is acute osteomyelitis and the subject has successfully completed IV antibiotic treatment prior to screening.\n7. Index ulcer is a minimum of 0.7cm2 and a maximum of 25cm2 at first treatment visit\n8. Diabetic foot ulcer is being treated with offloading therapy for 14 days prior to randomization\n9. Adequate circulation of ulcer demonstrated by an ABI of \\>0.7 and \\\u003C1.3, or TBI of \\>0.6 within 30 days prior to randomization OR an arterial ultrasound noted with patent circulation and without significant stenosis 90 days prior to randomization.\n10. Index ulcer is free of infection prior to randomization and during screening phase. Infection must be adequately treated and controlled as defined by Infectious Disease Society of America (IDSA) Guidelines PEDIS Grade 1.\n11. Index ulcer is free of necrotic debris prior to OCMTM application\n12. Female subjects of childbearing potential having a negative pregnancy test prior to randomization\n13. Subject is able and willing to follow the protocol requirements\n14. Subject had signed informed consent\n15. If 2 or more ulcers are present, the ulcers must be separated by at least 2 cm\n\nExclusion Criteria:\n\n1. Subject has a known life expectance of \\\u003C1 year\n2. Subject is unable to comply with protocol treatment\n3. Subject has major uncontrolled medical disorders in the opinion of the investigator, such as serious cardiovascular, renal, liver, pulmonary, autoimmune, palliative care, or inherited blood disorders that may affect wound healing\n4. Subject actively being treated for malignant disease or history of malignancy or radiation therapy at the site of wound\n5. Subject has comorbid conditions that may compromise subject safety in the opinion of the investigator\n6. Known contraindications to Acellular matrices\n7. Concurrent participation in alternative clinical trial that involves investigational drug or device interfering with wound treatment and\u002For healing\n8. Subject is pregnant or breastfeeding\n9. Subject with history of immunosuppressant treatment (systemic corticosteroids \\>10mg daily dose), cytotoxic chemotherapy, or topical steroid application to the ulcer surface for \\>2 weeks duration within 30 days prior to randomization; or anticipated use of the above during the course of the study\n10. Wound previously treated with CAMPs, tissue engineered, or scaffold materials within 30 days prior to randomization\n11. Diabetic foot ulcer of Wagner 3 grade with active acute infection that has not completed IV antibiotic treatment, or Wagner 3 grade with chronic refractory osteomyelitis\n12. Wound depth with visible exposed bone\n13. HBOT within 14 days prior to randomization\n14. Revascularization surgery on the index ulcer leg within 30 days of screening phase\n15. Index ulcer suspicious of neoplasm in the opinion of the principal investigator","ALL","18 Years",{"count":221,"type":222},130,"ESTIMATED","INTERVENTIONAL",[225],"NA","This study aims to compare two treatment approaches for diabetic foot ulcers (DFUs): the standard of care (SOC) alone versus SOC combined with OCM. Researchers will evaluate whether adding OCM increases the likelihood of ulcers healing completely by the end of the trial period.",[228],"Diabetic Foot Ulcer",[230,231],"Chronic Wounds","Wound Medicine","2026-06-12",{"date":234,"type":235},"2026-06-15","ACTUAL",{"date":237,"type":235},"2025-12-04",{"date":239,"type":222},"2027-03-30",{"name":5,"class":6},10]